CCCC

Announcements

Nothing here yet

Daily updates

• C4 Therapeutics reported IMS biomarker findings showing immunomodulatory effects of cemsidomide in relapsed or refractory multiple myeloma, including T-cell activation with dexamethasone and initial signals of T-cell proliferation with elranatamab.Sep 25, 2026

FDA designations

Nothing here yet

News

• C4 Therapeutics presents new biomarker findings from cemsidomide Phase 1 and Phase 1b studies in relapsed/refractory multiple myelomaSep 25, 2026
• C4 Therapeutics dosed the first patient in a Phase 1b trial of cemsidomide combined with elranatamab for multiple myelomaMar 25, 2026
• C4 Therapeutics outlined milestones to advance cemsidomide as IKZF1/3 degraderJan 14, 2026
• C4 Therapeutics announces clinical trial collaboration and supply agreement with Pfizer for combination of Cemsidomide and Elranatamab for treatment of relapsed/refractory multiple myelomaOct 1, 2025
• C4 Therapeutics presents Cemsidomide Phase 1 multiple myeloma data supporting potential best-in-class profile at International Myeloma Society Annual MeetingSep 22, 2025